HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

NCT05135364 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: HAIC
DRUG: TKI

Sponsor

Yue Han

Collaborators

[object Object]